Rimegepant: Effective Migraine Prevention for Resistant Cases

Research Summary

A recent study published in Cephalalgia evaluated the effectiveness and tolerability of rimegepant for preventing episodic migraines in adults who previously had inadequate responses to 2-4 types of traditional oral preventive medications. In this phase 4 trial, 328 participants took rimegepant, while 324 received a placebo over a 12-week period. The results showed that those taking rimegepant experienced a significant reduction in monthly migraine days compared to the placebo group, with a mean difference of 1.6 fewer days. All key secondary endpoints favored rimegepant, including improvements in pain reduction and quality of life. Rimegepant was well tolerated, with a safety profile similar to placebo.

Study Details

📄 Title: A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.

👥 Research Team: Pozo-Rosich P et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.